Along with its U.S. plans, Ranbaxy is working to expand generic sales in emerging markets. Those are heavily populated countries with a growing middle class and rising government spending on health care, from India and China to Brazil and Russia.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”